Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Long-acting echinocandin

Rezafungin

Brand names: Rezzayo

Rezafungin is a long-acting echinocandin antifungal used for the treatment of invasive candidiasis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the enzyme 1,3-beta-D-glucan synthase, disrupting fungal cell wall synthesis and leading to fungal cell death.

Prescribing in practice

  • Hypersensitivity and infusion-related reactions can occur; administer by intravenous infusion at a controlled rate with appropriate monitoring.
  • Its prolonged half-life allows once-weekly dosing, which differs from other echinocandins.
  • Echinocandins have limited activity against some non-Candida moulds, so confirm the pathogen and susceptibility where possible.

Monitoring

Monitor liver function and clinical and microbiological response to therapy.

Counselling the patient

  • This antifungal is given as a drip, usually once weekly.
  • Report any rash, flushing or breathlessness during the infusion.
  • Complete the full course as advised to clear the infection.

Evidence & guidelines

Rezafungin is an MHRA-authorised echinocandin for invasive candidiasis in adults.

Reference: NICE TA957; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways